| Catalog No. | HV716016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG4-IgG1, Lambda |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | OSMRB, IL-31R subunit beta, Oncostatin-M-specific receptor subunit beta, Interleukin-31 receptor subunit beta, IL-31RB, IL-31R-beta, OSMR, IL-31 receptor subunit beta |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | Q99650 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | KPL-716, 30C6(N73D), BIIB069, BIIB-069, 2243320-83-2 |
|---|
| Background | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.
• Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma., PMID:34087162
• Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease., PMID:28368383
• Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth., PMID:34380633
• Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology., PMID:26198770
• The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure., PMID:35163735
• Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts., PMID:38717842
• Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR., PMID:38569939
• AHNAK, regulated by the OSM/OSMR signaling, involved in the development of primary localized cutaneous amyloidosis., PMID:37100691
• Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma., PMID:24659184
• Targeting OSMR in glioma stem cells., PMID:28177884
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
